DARZALEX ® (daratumumab) Phase 3 MAIA Study Results Published in The New England Journal of Medicine Show Combination Therapy Increases Progression-Free Survival in Newly Diagnosed Patients with Multiple Myeloma Who are Transplant Ineligible

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news